GlassScriptPhysician profile
Stephen G Tygart
NPI 1033111703
$386.82
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.12 · 2020: $70.26 · 2021: $208 · 2022: $51.38.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59.50 | 2020-2021 | |
| Amgen INC. | $56.74 | 2020 | |
| Aspira Women'S Health INC | $54.46 | 2021 | |
| Channel Medsystems, INC. | $51.38 | 2022 | |
| Amag Pharmaceuticals, INC. | $34.40 | 2019 | |
| Duchesnay USA Incorporated | $22.72 | 2019 | |
| Hologic Sales and Service, LLC | $17.00 | 2021 | |
| Exeltis, USA INC. | $16.93 | 2021 | |
| Astellas Pharma US INC | $16.79 | 2021 | |
| Coloplast Corp | $15.90 | 2021 | |
| Convatec INC. | $15.34 | 2021 | |
| Mylan Pharmaceuticals INC. | $13.88 | 2021 | |
| Evofem Biosciences, INC. | $11.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tygart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.